Alnylam Files 8-K on Financial Results and Operations
Ticker: ALNY · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1178670
Sentiment: neutral
Topics: 8-K, financial-reporting, corporate-filing
TL;DR
**Alnylam just filed an 8-K announcing its financial results and operations, but the specific details aren't in this snippet.**
AI Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, to report on its Results of Operations and Financial Condition, and to include Financial Statements and Exhibits. This filing, identified by accession number 0001157523-24-000253, is a standard disclosure of the company's financial status.
Why It Matters
This filing indicates that Alnylam Pharmaceuticals, Inc. is providing an update on its financial performance and condition, which is essential for investors and stakeholders to assess the company's health and make informed decisions.
Risk Assessment
Risk Level: medium — This 8-K filing is a standard procedural announcement of financial reporting, and the provided text does not contain specific details to assess financial risk.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — registrant
FAQ
What type of SEC filing is this document?
This document is a Form 8-K.
What is the name of the company that filed this 8-K?
The company that filed this 8-K is Alnylam Pharmaceuticals, Inc.
What is the date of the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 15, 2024.
What specific items are being reported in this 8-K by Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. is reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for Alnylam Pharmaceuticals, Inc.?
The Central Index Key (CIK) for Alnylam Pharmaceuticals, Inc. is 0001178670.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-02-15 08:10:27
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq
Filing Documents
- a53896787.htm (8-K) — 27KB
- a53896787ex99_1.htm (EX-99.1) — 569KB
- 0001157523-24-000253.txt ( ) — 766KB
- alny-20240215.xsd (EX-101.SCH) — 4KB
- alny-20240215_lab.xml (EX-101.LAB) — 22KB
- alny-20240215_pre.xml (EX-101.PRE) — 16KB
- a53896787_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition On February 15, 2024, Alnylam Pharmaceuticals, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release dated February 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALNYLAM PHARMACEUTICALS, INC. Date: February 15, 2024 By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer